Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors

Karppinen, Noora; Lindén, Riikka; Sintonen, Harri; Tarkkanen, Maija; Roine, Risto P.; Heiskanen, Ilkka; Matikainen, Niina; Schalin‐Jäntti, Camilla

doi:10.1159/000494293

Cited by 16 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quality of life is an important measure of patients' perception of the burden of the disease and the impact of the different treatment modalities. Several studies have reported a worse HRQoL in GEP-NET patients compared to matched controls [80,81]. Particularly, NET patients reported poorer physical function, sleep disorders, discomfort, and depression.…”

Section: Impact Of Quality Of Lifementioning

confidence: 98%

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.

show abstract

Section: Impact Of Quality Of Lifementioning

confidence: 98%

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

show abstract

“…Regional lymphadenopathy is associated with desmoplasia of the mesentery forming a mesenteric mass . Mesenteric desmoplasia/mass causes abdominal pain and small bowel obstruction due to the kinking of the small bowel and mesenteric ischemia, which severely impairs the quality of life . Resection of the primary tumor, regional lymph nodes, and the mesenteric mass is recommended to manage such symptoms and for the possible prognostic benefit even in the setting of unresectable distant metastases .…”

Section: Introductionmentioning

confidence: 99%

“…8,11 Mesenteric desmoplasia/ mass causes abdominal pain and small bowel obstruction due to the kinking of the small bowel and mesenteric ischemia, which severely impairs the quality of life. 12,13 Resection of the primary tumor, regional lymph nodes, and the mesenteric mass is recommended to manage such symptoms and for the possible prognostic benefit even in the setting of unresectable distant metastases. 11,[14][15][16][17][18][19] The latest American Joint Committee on Cancer (AJCC) TNM staging for NETs of the jejunum and ileum (8th edition) defined a new category of N2 as a large mesenteric mass (LMM) >2 cm, 12 or more positive nodes, or involving the main superior mesenteric vessels.…”

mentioning

confidence: 99%

Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors

Kasai

Mahuron

Hirose

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives Ileal neuroendocrine tumors (i‐NETs) frequently metastasize to mesenteric lymph nodes and the liver. Regional lymphadenopathy is associated with desmoplasia of the mesentery forming a large mesenteric mass (LMM). Although the latest American Joint Committee on Cancer TNM staging (8th edition) defined LMM >2 cm as N2, the prognostic impact of LMM is ill‐defined. We evaluated whether LMM is prognostic for patients with i‐NETs. Methods This single‐institution, retrospective cohort study included 106 patients who underwent resection of i‐NETs between 2007 and 2018. Overall survival (OS) and liver progression‐free survival (LPFS) were compared between patients with and without LMM. Results LMM was present in 66 patients (62%) and was not associated with the presence or absence of liver metastasis (P = .969) or the extent of liver involvement (P = .938). OS and LPFS differed significantly between patients with and without LMM (5‐year OS rates of 64.8% and 92.9%, respectively, P = .011; 3‐year LPFS rates of 45.3% and 67.5%, respectively, P = .025). In multivariate analysis, LMM was an independent prognostic factor for both OS (hazard ratio: 4.69, 95% confidence interval: 1.63‐17.6) and LPFS (1.99, 1.08‐3.88). Conclusion LMM >2 cm is prognostic for OS and LPFS and represents aggressive tumor biology.

show abstract

“…Larsson et al[ 25 ] reported mean baseline HADS anxiety and depression scores of 4.6 (SD: 4.0) and 3.2 (SD: 2.7), respectively. Four studies applied the Short Form-36 (SF-36) questionnaire[ 9 , 46 - 48 ], three of which were cross-sectional studies. Other measures used include the SF-12[ 49 ], the Functional Assessment of Cancer Therapy-Anaemia[ 50 ] and the Functional Assessment of Chronic Illness Therapy-Diarrhoea (FACIT-D).…”

Section: Resultsmentioning

confidence: 99%

Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

Watson¹,

Tallentire²,

Srirajaskanthan

et al. 2020

WJG

View full text Add to dashboard Cite

BACKGROUND Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GI-NETs) or the pancreas (P-NETs). They are relatively uncommon, accounting for 2% of all gastrointestinal malignancies. The usual treatment options in advanced GEP-NET patients with metastatic disease include chemotherapy, biological therapies, and peptide receptor radionuclide therapy. Understanding the impact of treatment on GEP-NET patients is paramount given the nature of the disease. Health-related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation, severity and treatment. AIM To conduct a systematic literature review to identify literature reporting HRQoL data in patients with GEP-NETs between January 1985 and November 2019. METHODS The PRISMA guiding principles were applied. MEDLINE, Embase and the Cochrane library were searched. Data extracted from the publications included type of study, patient population data (mid-gut/hind-gut/GI-NET/P-NET), sample size, intervention/comparators, HRQoL instruments, average and data spread of overall and sub-scores, and follow-up time for data collection. RESULTS Forty-three publications met the inclusion criteria. The heterogeneous nature of the different study populations was evident; the percentage of female participants ranged between 30%-60%, whilst average age ranged from 53.8 to 67.0 years. Eight studies investigated GI-NET patients only, six studies focused exclusively on P-NET patients and the remaining studies involved both patient populations or did not report the location of the primary tumour. The most commonly used instrument was the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 ( n = 28) with consistent results across studies; the GI-NET-specific module Quality of Life Questionnaire-GINET21 was used in six of these studies. A number of randomised trials demonstrated no HRQoL changes between active treatment and placebo arms. The Phase III NETTER-1 study provides the best data available for advanced GEP-NET patients; it shows that peptide receptor radionuclide therapy can significantly improve GEP-NET patients’ HRQoL. CONCLUSION HRQoL instruments offer a means to monitor patients’ general disease condition, disease progression and their physical and mental well-being. Instruments including the commonly used European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and GINET21 lack, however, validation and a defined minimal clinical important difference specifically for GI-NET and P-NET patients.

show abstract

Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors

Cited by 16 publications

References 34 publications

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors

Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

Contact Info

Product

Resources

About